CBT Pharmaceuticals Inc., of Pleasanton, Calif., said the first subject was dosed in a phase I study testing CBT-101, a specific oral inhibitor of the c-Met kinase. Following identification of a dose for CBT-101, the 68-patient trial is planned to expand into tumor-specific cohorts.